E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
This is a pharmacokinetic study in patients who have had a Subarachnoid Haemorrhage and who have had an external ventricular drain inserted for clinical management reasons, must usually for the treatment of hydrocephalus. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10042316 |
E.1.2 | Term | Subarachnoid haemorrhage |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052947 |
E.1.2 | Term | Ventricular drainage |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020508 |
E.1.2 | Term | Hydrocephalus |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the administration regime of intravenous (iv) Kineret® that will achieve a cerebrospinal fluid (CSF) concentration of 100 ng/ml within 30 minutes of the start of treatment in subarachnoid haemorrhage (SAH) patients. This will inform potential Phase III studies of Kineret® in SAH and stroke |
|
E.2.2 | Secondary objectives of the trial |
• To define the dose relationship between central and peripheral concentrations of Kineret® • To explore the impact of varying concentrations of Kineret® on inflammatory biomarkers in blood and cerebrospinal Fluid. • To obtain further safety information on serious adverse events (SAEs) and adverse events (AEs) in SAH patients given iv infusion of Kineret®.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria for study enrollment. • Patients with confirmed spontaneous SAH who are thought likely to, or are known to require,the placement of an EVD as part of their clinical care. Also, patients who have already had an EVD placed will be eligible. • No concomitant health problems that, in the opinion of the Principal Investigator or Chief Investigator or designee, would interfere with participation, administration of study treatment or assessment of outcomes including safety, for example, pre-existing malignancy. • No confirmed or suspected serious infection at the time of study entry. • Renal function within normal limits (serum creatinine< 177 µmol/l). • Willing and able to give informed consent or consent available from a patient representative (usually next of kin) for study inclusion including agreement in principle to receive study intervention and undergo all study assessments. • Aged 16 years or above.
Eligibility Criteria for Study Entry (to receive study intervention). In addition to meeting the requirements specified above, patients who are entered fully into the study will also meet the following criteria: Inclusion • EVD in place that is expected to remain in situ for the next 24-48 hours. • Likely to remain resident within the centre for the next seven days. • Willing to consent to inclusion in the study or consent available from the patient’s representative on the patient’s behalf.
|
|
E.4 | Principal exclusion criteria |
Exclusion Criteria for Study Enrolment • Unconfirmed or uncertain diagnosis of spontaneous SAH. • Known or suspected infection at the time of consideration for the study. • Impaired renal function defined as serum Creatinine > 177 µmol/l. • Known allergy to E. coli or any of the constituents of the study medication as established from the patient themselves, reliable representative and clinical records. • Previous or concurrent treatment with anakinra or Kineret®, known at the time of study entry. • Previous or current treatment with medication suspected of interacting with Kineret®, such as TNF-α inhibitors. • Evidence of serious infection. • Known to have participated in a clinical trial of an investigational agent or device in the previous 30 days or for the period determined by the protocol of the study the patient has taken part in. • Known pregnancy or breast-feeding. • Clinically significant concurrent medical condition, at the Chief Investigator’s (or designee’s) discretion, which could affect the safety, tolerability, or efficacy in this study. • Previous inclusion in the current study (known prior to inclusion). • Inability or unwillingness of patient or patient’s personal representative to give informed consent. • Aged below 16.
Exclusion from full study entry (to receive study intervention). • EVD not placed. • EVD is expected to be removed within 24 h. • Likely to be transferred from the centre within the next seven days. • Unwilling to consent to inclusion in the study or consent unavailable from the patient’s representative on the patient’s behalf.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint: 1. CSF and plasma concentrations of Kineret® at 30 minutes post-commencement of infusion
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
dose ranging/determination study |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be the last assessment visit for the final patient included in the study. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 24 |
E.8.9.2 | In all countries concerned by the trial days | 0 |